Medtronic has announced that the US Food and Drug Administration (FDA) has approved the Affera mapping and ablation system featuring the Sphere-9 Catheter. This innovative, all-in-one system combines ...

Medtronic plc MDT recently announced the receipt of a CE Mark for the Affera Mapping and Ablation System to treat atrial arrhythmias. The system includes the Sphere-9 Catheter and the Affera Prism-1 ...

HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life DUBLIN and BOSTON, May 17, 2024 ...

Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report) and keeping the price target at $100.00. Travis Steed has given his Buy rating due to ...

NEWTON, Mass., Dec. 20, 2021 /PRNewswire/ -- Affera Inc., a private medical device company focused on innovative cardiac arrhythmia treatment solutions, announced today that the first patient was ...

First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform The Sphere-9 Catheter, ...

Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias ...

One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy ...

Medtronic is acquiring Affera Inc., a medical technology company focused on treating cardiac arrhythmias, for $925 million. While Medtronic declined Monday to share the sale price, analysts at Piper ...

HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life "These are excellent results for ...